Brown, Dexcom Head of Market Access discusses diabetes management. The views expressed here are not necessarily those of The Scotsman and it is recommended to always seek NHS advice before commencing ...

Dexcom unveiled its Dexcom G7 continuous glucose monitoring (CGM) for people with diabetes age two years and older in ...

Dexcom announced today that its G6 continuous glucose monitor (CGM) is being worn by astronauts as part of the Polaris Dawn ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

DexCom (NASDAQ: DXCM) is a big name in diabetes care. Its continuous glucose monitors (CGMs) help people track their blood glucose levels. But the stock has been performing poorly this year amid ...

today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being worn by astronauts in space as part of the Polaris Dawn mission, which launched this morning and aims to better ...

Investors have been bearish on DexCom's numbers all this past year. The opportunity in diabetes care, however, remains significant in the long run. The launch of glucose monitor Stelo should ...

If you invested in DexCom, Inc. you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you.

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing ...